Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (1965)	11/6/2000 12:06:15 PM
From: scott_jiminez	Respond to of 52153

Thanks Mark. I've gotta run but just wanted you to be aware that I had studied CardioDynamics when initially investigating HDII, including many of the issues of concern to you. I concluded that HDII had a more rigorous product and a clear and aggressive business plan. Undoubtedly, I could be wrong (though my experience over the last ~6-9 months has done nothing to change my opinion). I would encourage you to visit HDI's website, and to read their press releases and SEC filings, to better understand their products and management team. This would also allow you to absorb HDI's awareness of the complexity of the marketplace....and their plans to gain a foothold in it. In parallel to your perception of CDIC, the partnership links I provided in my previous post provides a framework that '...will translate into sales and profits, and hence stock appreciation.' for HDII as well. Best wishes, Scott

To: Mark Bong who wrote (1965)	11/7/2000 7:42:36 AM
From: scott_jiminez	Respond to of 52153

Mark - the following is the result of (your insightful questions and) a conversation with IR at HDII: HDII and CDIC are not competing for the same market. The device that won FDA approval for HDII on Friday assesses arterial elasticity (as a gauge of cardiovascular integrity). This is accomplished through waveform analysis of cardiac output following a 30 sec. measurement in a doctors office. Assessment is the key word here. CDIC's device is incorporated into a series of machines which monitors a patient's cardiovascular status over time. Some of CDIC's measurements overlap with those of the HDII readings; however, the two devices were designed, and are used, for very different purposes. HDII's profilor is intended for an in-office assessment of CV integrity; CDIC's device is intended as a component of chronic monitoring of CV status. Neither can produce the data of the other. Other issues... HDII is a very small company at present. There's little debate that the FDA approval is about to change that dramatically. The company is very conservative about this transition phase and is proceeding with extreme caution so as not to jump forward (for example, immediately quadrupling its sales force) too fast. They are completely aware of the reimbursement maze and, with the approval now behind them, this is priority one. They have spoken with the AMA regarding the 'reimbursability' of the profilor; while there is nothing else like it extant, they were told that some of the existing CPT codes approximate the use of the profilor so that a transition to reimbursement for HDII will likely not have to be initiated from ground zero. Certainly no guarantees; HDII is focusing most of their current energies on establishing the contacts and environment necessary for payers to support the profilor. The central message was that they plan to do proceed with methodical caution so as not to be caught in the trap of rapid expansion and devoid of cash. Their CR-2000 device (for research only) continues to sell well; the exposure they receive with this, especially with physicians who conduct research while maintaining a clinical practice, has given them an invaluable foot-in-the-door for the introduction of the now clinically approved device. This, along with the recent selection by Pfizer to use the CR-2000 in a large, nationwide study, continues to give the company exposure precisely in the market where it intends to sell the clinical profilor. Consistent with the tone of the entire conversation, the spokesman made no specific leading comments regarding strategic partners for marketing (even when pressed regarding Pfizer) other than to state they were proceeding in a controlled fashion and will have announcements in the near future. This information is obvious severely tinted by the viewpoint of the company; such a perspective demands extreme caution and overriding skepticism. Nevertheless, I was pleased with their conservative approach towards the future. I hope this helps. Good luck. Scott